- Home
- MDCX
MDCX
Medicus Pharma Ltd. Common Stock
as 12-18-2024 11:39am EST
Stocks
| Founded: | 2008 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 26.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.80 - $3.23 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Medicus Pharma Ltd. Common Stock News
MDCX Breaking Stock News: Dive into MDCX Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Medicus Pharma up 9% in Pre-market Trading as FDA Approves Anti-cancer Patch for Horses
GlobeNewswire
6 days ago
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
Clinical Trials Arena
15 days ago
Medicus Pharma and Swanielle partner to expand BCC drug trial to Asia-Pacific
Newsfile
16 days ago
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
Zacks Small Cap Research
21 days ago
MDCX: Medicus Pharma 3Q 2024 Financial Results Reported; Stock Now Trades Both in Canada and on Nasdaq After Completing an IPO in the U.S.
Zacks Small Cap Research
23 days ago
V.MDCX: Medicus Pharma Has Begun Trading on Nasdaq under the ticker MDCX after Completing an IPO in the U.S. The SKNJCT-003 Phase 2 clinical trial continues.
Zacks Small Cap Research
23 days ago
V.MDCX: Medicus Pharma Has Begun Trading on Nasdaq under the ticker MDCX after Completing an IPO in the U.S. The SKNJCT-003 Phase 2 clinical trial continues.
Compare MDCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDCX Medicus Pharma Ltd. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.